Selected References

PI Tenbusch/PI Lapuente

• Schmidt A, Paudyal B, Villanueva-Hernández S, Mcnee A, Vatzia E, Carr BV, Schmidt S, Mccarron A, Martini V, Schroedel S, Thirion C, Waters R, Salguero FJ, Gerner W, Tenbusch M, Tchilian E. Effect of mucosal adjuvant IL-1β on heterotypic immunity in a pig influenza model Front Immunol. 2023 Apr 20; 14: 1181716.
• Irrgang P, Gerling J, Kocher K, Lapuente D, Steininger P, Habenicht K, Wytopil M, Beileke S, Schäfer S, Zhong J, Ssebyatika G, Krey T, Falcone V, Schülein C, Peter AS, Nganou-Makamdop K, Hengel H, Held J, Bogdan C, Überla K, Schober K, Winkler TH, Tenbusch M. (2023) Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci Immunol. 2023 Jan 27; 8(79): eade2798.
• Reimann H, Kremer AN, Blumenberg V, Schmidt KG, Aigner M, Jacobs B, Eisenhauer N, Kämpf A, Roesler W, Kharboutli S, Mougiakakos D, Lang V, Lischer C, Irrgang P, Leppkes M, Gonzalez JV, Krönke G, Kremer AE, Tenbusch M, Bruns H, Harrer T, Müller F, Schett G, Mackensen A, Subklewe M, Völkl S (2022). Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR-T cell therapy. Blood Adv. 2022 Oct 7: bloodadvances. 2022007806.
• Vogel E, Kocher K, Priller A, Cheng CC, Steininger P, Liao BH, Körber N, Willmann A, Irrgang P, Held J, Moosmann C, Schmidt V, Beileke S, Wytopil M, Heringer S, Bauer T, Brockhoff R, Jeske S, Mijocevic H, Christa C, Salmanton-García J, Tinnefeld K, Bogdan C, Yazici S, Knolle P, Cornely OA, Überla K, Protzer U*, Schober K*, Tenbusch M*. (2022) Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2 EBioMedicine. Nov; 85: 104294.
• Maier C, Fuchs J, Irrgang P, Wißing MH, Beyerlein J, Tenbusch M*, Lapuente D*. (2022) Mucosal immunization with an adenoviral vector vaccine confers superior protection against RSV compared to natural immunity. Front Immunol. Jul 28; 13: 920256.
• Lapuente D, Fuchs J, Willar J, Vieira Antão A, Eberlein V, Uhlig N, Issmail L, Schmidt A, Oltmanns F, Peter AS, Mueller-Schmucker S, Irrgang P, Fraedrich K, Cara A, Hoffmann M, Pöhlmann S, Ensser A, Pertl C, Willert T, Thirion C, Grunwald T, Überla K, Tenbusch M. (2021b) Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization Nat Commun. Nov 26; 12(1): 6871.
• Schmidt KG, Nganou-Makamdop K, Tenbusch M, El Kenz B, Maier C, Lapuente D, Überla K, Spriewald B, Bergmann S, Harrer EG, Harrer T (2021). SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses. Front Immunol. 2021 Apr 28; 12: 627568.
• Kremer AE, Kremer AN, Willam C, Völkl S, Verhagen J, Achenbach S, van der Meijden ED, Lang V, Aigner M, Maier C, Tenbusch M, Korn K, Lutzny-Geier G, Spoerl S, Strauß R, Vetter M, Überla K, Neurath MF, Mackensen A, Schiffer M, Hackstein H.(2021) Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity. Eur J Immunol. 2021 Oct; 51(10): 2478-2484.
• Tenbusch M, Schumacher S, Vogel E, Priller A, Held J, Steininger P, Beileke S, Irrgang P, Brockhoff R, Salmanton-García J, Tinnefeld K, Mijocevic H, Schober K, Bogdan C, Yazici S, Knolle P, Cornely OA, Überla K, Protzer U (2021). Lancet Infect Dis. Sep; 21(9): 1212-1213.
• Schmidt A, Lapuente D (2021).T-cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine. Viruses. 2021 Jan 28; 13(2): 199.
• Lapuente D, Maier C, Irrgang P, Hübner J, Peter AS, Hoffmann M, Ensser A, Ziegler K, Winkler TH, Birkholz T, Kremer AE, Steininger P, Korn K, Neipel F, Überla K, Tenbusch M (2021a) Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2. Eur J Clin Microbiol Infect Dis. 2021 Apr; 40(4): 751-759.
• Simon D, Tascilar K, Krönke G, Kleyer A, Zaiss MM, Heppt F, Meder C, Atreya R, Klenske E, Dietrich P, Abdullah A, Kliem T, Corte G, Morf H, Leppkes M, Kremer AE, Ramming A, Pachowsky M, Schuch F, Ronneberger M, Kleinert S, Maier C, Hueber AJ, Manger K, Manger B, Berking C, Tenbusch M, Überla K, Sticherling M, Neurath MF, Schett G (2020). Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion. Nat Commun. 2020 Jul 24; 11(1): 3774.
•  Lapuente, D., Storcksdieck genannt Bonsmann, M., Maaske, A., Stab, V., Heinecke, V., Watzstedt, K., Heß, R., Westendorf, A.M., Bayer, W., Ehrhardt, C., Tenbusch, M. (2018b). IL-1β as mucosal vaccine adjuvant: The specific induction of tissue-resident memory T cells improves the heterosubtypic immunity against influenza A viruses. Mucosal Immunol. 11: 1265-2178.
• Lapuente, D., Ruzsics, Z., Thirion, C., Tenbusch, M. (2018a). Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses. Vaccine. 36(19): 2712-2720.